May 13 2010
CEO of The Russian Corporation of Nanotechnologies Anatoly Chubais and MP Biomedicals CEO Milan Panic have signed an agreement of cooperation. The parties have agreed to cooperate in organization of nanotechnology research and development, in creation and modernization of R+D base, and in providing due conditions for production of innovative pharmaceuticals, including personal pharmacogenetic treatments.
RUSNANO and MP Biomedicals plan to jointly implement projects aimed at the increase in life expectancy and anti-aging as well as creating infrastructure for innovations in the area of nanobiotechnology.
The parties have agreed to participate in the work of scientific, coordinating and other councils, expert commissions and working groups on nanobiotechnology and pharmaceutical industry, that relate to areas of the signed agreement. RUSNANO and MP Biomedicals also decide to jointly provide mutual methodological and scientific-medical support for studies of the nanotechnology.
RUSNANO and MP Biomedicals will also collaborate in creating the information infrastructure to ensure the establishment and support of databases on scientific and medical developments and innovative projects in the field of biotechnology, pharmaceutical industry and nanotechnology.
The parties will elaborate the long-term forecast for areas of nanotechnology application in the field of life sciences, pharmaceutics and related industries with the allocation of promising emerging markets, products and services, as well as a list of priorities and critical technologies in the pharmaceutical industry. In addition, RUSNANO and MP Biomedicals will consider investments in the regions with already developed pharmaceutical industry.